Perioperative Chemotherapy in Locally Advanced Gastric Cancer

Batista, Thales Paulo; Santos, Cleusa Lapa; Almeida, Gustavo Fernandes Godoy

doi:10.1590/s0004-28032013000200042

Cited by 7 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 In particular, chemotherapy has been approved as a treatment option for gastrointestinal cancers. 3 Unfortunately, in GC patients with chemotherapeutic drugs, tumor metastasis and local recurrence become increasingly common due to chemoresistance. 4 Autophagy is a homeostatic process in which the aged and damaged proteins or certain organelles of the cell are encapsulated into vesicles, and were bound with lysosomes to form autophagic lysosomes, and finally were degraded as the contents encapsulated by autophagy-related genes (ATGs) under starvation, hypoxia or other specific cellular stress conditions.…”

Section: Introductionmentioning

confidence: 99%

Facing Cell Autophagy in Gastric Cancer – What Do We Know so Far?

Xiu

Guo

Jing

2021

IJGM

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Facing Cell Autophagy in Gastric Cancer – What Do We Know so Far?

Xiu

Guo

Jing

2021

IJGM

View full text Add to dashboard Cite

“…At present, the standard therapy for gastric carcinoma includes surgical intervention followed by combination chemotherapy (22). While chemotherapy has become the primary treatment option for advanced gastric carcinoma (23), the effect of traditional chemotherapy is not ideal. Targeted therapy is a novel cancer treatment at the cellular or molecular level (24), in which specially designed drugs can target and act on the specific genes or proteins necessary for tumor growth.…”

Section: Introductionmentioning

confidence: 99%

Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway

2021

View full text Add to dashboard Cite

Gastric carcinoma is a common type of gastrointestinal tumor with high morbidity and mortality rates. IL-17 is a newly discovered cytokine that has been reported to serve an important role in the development of gastric carcinoma. The potential effect of apatinib on IL-17 expression levels in the development of gastric carcinoma has been rarely reported. The present study aimed to investigate the potential mechanism of IL-17 and apatinib in the development of gastric carcinoma. A total of 30 tumor and para-carcinoma tissues were collected from 30 patients with gastric carcinoma between January 2019 and December 2019 and the expression levels of IL-17 in the tissues were analyzed by reverse transcription-quantitative PCR and western blotting. An in vitro model of gastric carcinoma was also established using the HGC-27 cell line, in which the cells were divided into control, IL-17, IL-17-apatinib and apatinib groups. The expression levels of IL-17, Bax, Bcl-2 and caspase-3 were analyzed using reverse transcription-quantitative PCR and western blotting. An MTT assay and flow cytometry were used to analyze the proliferation and apoptosis of HGC-27 cells, respectively, and a Transwell assay was used to analyze the invasive ability of HGC-27 cells. The results revealed that the expression levels of IL-17 were significantly upregulated in the gastric carcinoma tissues compared with the para-carcinoma tissues. In vitro, IL-17 treatment promoted the proliferation and invasive ability of HGC-27 cells, but inhibited the apoptosis with the significantly downregulated expression levels of Bax and caspase-3 and the upregulated expression levels of Bcl-2 than control group. Conversely, apatinib treatment significantly inhibited the proliferative and invasive abilities of HGC-27 cells, but promoted cell apoptosis in the IL-17 and IL-17-apatinib groups.. Collectively, the present results suggested that the upregulation of IL-17 may be associated with the occurrence and development of gastric carcinoma. The findings indicated that apatinib may inhibit gastric carcinoma development by regulating IL-17 expression via the Bax/Bcl-2 signaling pathway. Therefore, the present findings may enhance the current knowledge of the effect of apatinib on gastric carcinoma cells.

show abstract

“…Gastric cancer (GC) is the fifth highest incidence malignant tumor in the world and the third dominant cause of cancer death, with a 5-year survival rate of only 20% to 25% worldwide [1, 2]. Despite the improvement of therapeutic methods with surgical resection, chemotherapy, radiotherapy, immunotherapeutic strategies, and targeted therapies, invasion and metastasis lead to the poor prognosis of GC patients and have become a significant clinical challenge [3–7]. Therefore, finding new molecular markers which are related to metastasis and poor outcome may contribute to affording new insights into diagnostic decision and novel therapies for GC patients.…”

Section: Introductionmentioning

confidence: 99%

ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells

Xie

Liu

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Annexin A2 (ANXA2) has been well known to associate with the progress of malignant tumor. However, the biological behavior of ANXA2 in gastric cancer (GC) remains unclear. We made a hypothesis in transcriptome level from TCGA datasets. Then, we used immunohistochemical staining to quantify the expression level of ANXA2 protein in GC tissues compared with adjacent tissues. Quantitative real-time PCR and western blot were used for analyzing ANXA2 expression in human GC (SGC-7901, MKN-45, BGC-823, and AGS) cell lines. We investigated the effect of a lentivirus-mediated knock-down of ANXA2 on the proliferation, invasion and migration of gastric cancer AGS cells. Cell proliferation was examined by MTT and colony formation tests. Cell apoptosis and cycle were measured by flow cytometry. Migration and invasion were detected by transwell assay. We found that high expression of ANXA2 can increase the mobility of cancer cells from TCGA datasets. ANXA2 was upregulated in GC tissues compared with adjacent tissues. AGS cell line displayed significantly higher expression of ANXA2 among the four GC cell lines. In addition, ANXA2 silencing led to a weakened ability of proliferation, invasion, and migration in GC cells; targeting of ANXA2 may be a potential therapeutic strategy for GC patients.

show abstract

Perioperative Chemotherapy in Locally Advanced Gastric Cancer

Cited by 7 publications

References 57 publications

Facing Cell Autophagy in Gastric Cancer – What Do We Know so Far?

Facing Cell Autophagy in Gastric Cancer – What Do We Know so Far?

Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway

ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells

Contact Info

Product

Resources

About